Of note, the small molecule CCR1 antagonist CCX354 has shown efficacy in a phase II clinical trial for the treatment of rheumatoid arthritis and larger, longer-term clinical trials have been planned42. The gene discussed is CCR1; the disease is rheumatoid arthritis.